文献速递肿瘤 PET/CT

使用放射性标记抗体TAT偶联物与SPECT对癌症小鼠模型中的p53进行分子成像

Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT.
PubMed 文献 · J Nucl Med · 2024-10-01

研究将抗p53单克隆抗体与细胞穿透转录激活因子(TAT)肽及金属离子螯合剂偶联,再用111In放射性标记,实现在三种癌症模型中经SPECT无创可视化肿瘤组织p53。111In-抗p53-TAT在高表达p53R175H和中表达野生型p53的肿瘤异种移植中摄取高于111In-mIgG-TAT对照,在p53缺失肿瘤中无此差异;结果在KPC小鼠来源胰腺导管腺癌模型及携带自发p53R172H胰腺导管腺癌的KPC小鼠中得到验证。作者结论为该方法可行。

要点

  • 111In-抗p53-TAT在高表达p53R175H和中表达野生型p53肿瘤中摄取高于111In-mIgG-TAT对照。
  • 在p53缺失肿瘤异种移植中未见111In-抗p53-TAT摄取高于对照。
  • 在KPC小鼠来源胰腺导管腺癌及携带自发p53R172H胰腺导管腺癌的KPC小鼠中完成成像验证。

核心结论

  • 作者证明使用放射性标记TAT修饰单克隆抗体对肿瘤组织p53进行无创体内分子成像是可行的。

研究设计与样本

  • 研究在3种癌症模型中用SPECT进行体内成像,使用111In标记的抗p53单克隆抗体与TAT肽及金属离子螯合剂偶联物。

主要发现

  • 111In-抗p53-TAT偶联物在过表达p53特异性细胞的保留时间比非p53特异性111In-mIgG-TAT对照更长,但在p53缺失细胞中无此差异。
  • 体内SPECT显示111In-抗p53-TAT在高表达p53R175H和中表达野生型p53肿瘤异种移植中摄取高于111In-mIgG-TAT,在p53缺失肿瘤异种移植中未见提高。
  • 结果在携带基因工程KPC小鼠来源胰腺导管腺癌肿瘤的小鼠中得到确认。
  • 在携带自发p53R172H胰腺导管腺癌肿瘤的KPC小鼠中可用111In-抗p53-TAT完成成像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations of p53 protein occur in over half of all cancers, with profound effects on tumor biology. We present the first-to our knowledge-method for noninvasive visualization of p53 in tumor tissue in vivo, using SPECT, in 3 different models of cancer. Methods: Anti-p53 monoclonal antibodies were conjugated to the cell-penetrating transactivator of transcription (TAT) peptide and a metal ion chelator and then radiolabeled with 111In to allow SPECT imaging. 111In-anti-p53-TAT conjugates were retained longer in cells overexpressing p53-specific than non-p53-specific 111In-mIgG (mouse IgG from murine plasma)-TAT controls, but not in null p53 cells. Results: In vivo SPECT imaging showed enhanced uptake of 111In-anti-p53-TAT, versus 111In-mIgG-TAT, in high-expression p53R175H and medium-expression wild-type p53 but not in null p53 tumor xenografts. The results were confirmed in mice bearing genetically engineered KPC mouse-derived pancreatic ductal adenocarcinoma tumors. Imaging with 111In-anti-p53-TAT was possible in KPC mice bearing spontaneous p53R172H pancreatic ductal adenocarcinoma tumors. Conclusion: We demonstrate the feasibility of noninvasive in vivo molecular imaging of p53 in tumor tissue using a radiolabeled TAT-modified monoclonal antibody.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Alakonya H, Koustoulidou S, Hopkins SL, et al. Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT. J Nucl Med. 2024. PMID: 39266290. doi:10.2967/jnumed.124.267736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。